98%
921
2 minutes
20
The greatest HIV-1 genetic diversity is found in West/Central Africa due to the pandemic’s origins in this region, but this diversity remains understudied. We characterized HIV-1 subtype diversity (from both sub-genomic and full-genome viral sequences), drug resistance and coreceptor usage in 103 predominantly (90%) antiretroviral-naive individuals living with HIV-1 in Ghana. Full-genome HIV-1 subtyping confirmed the circulating recombinant form CRF02_AG as the dominant (53.9%) subtype in the region, with the complex recombinant 06_cpx (4%) present as well. Unique recombinants, most of which were mosaics containing CRF02_AG and/or 06_cpx, made up 37% of sequences, while “pure” subtypes were rare (<6%). Pretreatment resistance to at least one drug class was observed in 17% of the cohort, with NNRTI resistance being the most common (12%) and INSTI resistance being relatively rare (2%). CXCR4-using HIV-1 sequences were identified in 23% of participants. Overall, our findings advance our understanding of HIV-1 molecular epidemiology in Ghana. Extensive HIV-1 genetic diversity in the region appears to be fueling the ongoing creation of novel recombinants, the majority CRF02_AG-containing, in the region. The relatively high prevalence of pretreatment NNRTI resistance but low prevalence of INSTI resistance supports the use of INSTI-based first-line regimens in Ghana.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865111 | PMC |
http://dx.doi.org/10.3390/v15010128 | DOI Listing |
South Afr J HIV Med
July 2025
The Janssen Pharmaceutical Companies of Johnson & Johnson, Cape Town, South Africa.
Background: Evaluating long-term efficacy, safety and pharmacokinetics of long-acting cabotegravir + rilpivirine (CAB+RPV LA) in sub-Saharan African populations is important because of the region's unique demographics and antiretroviral therapy resistance patterns.
Objectives: To describe the 96-week efficacy, safety and pharmacokinetics of CAB+RPV LA in South African participants from the pooled FLAIR and ATLAS-2M Phase 3/3b randomised studies.
Method: Primary endpoint: proportion of participants with plasma HIV-1 RNA levels ≥ 50 copies/mL at Week 96.
BMC Infect Dis
August 2025
Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana.
In Ghana, cerebrospinal fluid polymerase chain reaction (PCR) is the primary diagnostic tool for viral encephalitis. However, its application remains limited, and diagnosis is predominantly syndromic. Current data on encephalitis in Ghana are sparse and often restricted to sporadic cases, with improved PCR diagnostics elucidating some aetiological agents but leaving approximately 60% of cases undiagnosed.
View Article and Find Full Text PDFAIDS Res Ther
July 2025
Division of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
HIV drug resistance (HIVDR) was retrospectively characterized among 20 children and adolescents with HIV with virologic failure on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, and virologic response in those switched to dolutegravir (DTG)-based therapy described. All participants had at least one NNRTI resistance mutation, most commonly K103N (N = 12) and 15 (75%) had nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, most commonly M184I/V (N = 15). Five (45%) of 11 participants who were switched to DTG-based regimens for a median of 50 months had HIV suppression.
View Article and Find Full Text PDFSci Rep
July 2025
Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
For the entry of R5 human immunodeficiency virus type 1 (HIV-1) into target cells, CCR5 functions as a coreceptor following the binding of the envelope glycoprotein gp120 to the receptor CD4. While CD4 is known to be strongly downregulated after infection, the fate of CCR5 post-infection remains unclear. We investigated the surface expression of CCR5 on PM1/CCR5 cells following infection with HIV-1.
View Article and Find Full Text PDFInt J Microbiol
July 2025
West African Centre for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Two distinct types of human immunodeficiency virus (HIV), namely, HIV-1 and HIV-2 exist. HIV-1 is responsible for the global pandemic and has an aggressive pathogenesis. On the contrary, HIV-2 is not only less aggressive but also confined to West and Central African regions.
View Article and Find Full Text PDF